DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Net Income
Bottom-line profit after all expenses, interest, and taxes.
DarioHealth Corp.NASDAQ: DRIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$8.25M, compared with -$9.23M a year earlier. Trailing-twelve-month net income was $62.71M.
Context
- Net income amounted to 186.6% of revenue in FY2025, up 28.5 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$206.54M (-395.1%) for the fiscal year ending Dec 2026, a slowdown from the +2.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.25M-109.6% QoQ
- Last fiscal yearDec 2025
- -$41.71M+2.4% YoY
- LTMMar 2026
- $62.71M+240.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.6% | +12.6% | +2.0 pp |
| 1 year | +2.4% | -395.1% | -397.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (41.71M) USD
- Year-over-year change
- +2.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.71M) | +2.4% |
| FY2024 | 2024-12-31 | (42.75M) | +28.1% |
| FY2023 | 2023-12-31 | (59.43M) | +4.4% |
| FY2022 | 2022-12-31 | (62.19M) | +19.0% |
| FY2021 | 2021-12-31 | (76.76M) | — |
Net Income vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 net income of $62.71M is the highest of the 11 companies compared; the peer median is -$96.12M.
- Its year-over-year change of +240.0% is the highest of 11, against a peer median of +9.4%.
- Net income amounts to 295.9% of revenue for DRIO, versus a peer median of 61.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $62.71M | +240.0% | — | 295.9% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $7.23M | +204.6% | -10.3% | 74.1% |
| LTM Mar 2026 | -$22.2M | +28.9% | — | 2.3% | |
| LTM Mar 2026 | -$60.01M | +58.1% | — | 7.3% | |
| LTM Mar 2026 | -$69.4M | +82.0% | — | 9.7% | |
| LTM Mar 2026 | -$73.81M | -81.0% | — | 23.0% | |
| LTM Mar 2026 | -$118.44M | -10.2% | — | 6450.8% | |
| LTM Mar 2026 | -$128.58M | +80.5% | — | 80.3% | |
| LTM Mar 2026 | -$193.96M | -30.3% | — | 391.2% | |
| LTM Mar 2026 | -$290.01M | -83.9% | — | 330.2% | |
| LTM Mar 2026 | -$399.9M | -294.4% | — | 48.2% | |
| Peer median (excluding DRIO) | -$96.12M | +9.4% | -10.3% | 61.1% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.51M | 27.66M | 20.35M | 27.04M | 22.36M |
| Cost of Revenue | 12.44M | 18M | 14.37M | 13.77M | 9.69M |
| Gross Profit | 8.07M | 9.66M | 5.98M | 13.27M | 12.67M |
| Gross Margin | 39.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Research & Development | 17.22M | 19.65M | 20.25M | 24.18M | 13.79M |
| Selling, General & Admin | 62.36M | 46.82M | 41.8M | 46.83M | 35.53M |
| Operating Expenses | 84.56M | 66.47M | 62.17M | 71.01M | 49.32M |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 3.56M |
| EBITDA | (70.02M) | (55.6M) | (54.38M) | (37.08M) | (34.69M) |
| EBITDA Margin | -341.3% | -201.0% | -267.2% | -137.1% | -155.2% |
| Operating Income | (76.49M) | (56.81M) | (56.19M) | (57.74M) | (36.66M) |
| Operating Margin | -372.9% | -205.4% | -276.1% | -213.6% | -163.9% |
| Interest Income | 44K | 506K | 1.87M | 1.12M | 943K |
| Interest Expense | 84K | 2.68M | 645K | 96K | 3.36M |
| Other Income / Expenses | (235K) | (5.38M) | (3.17M) | 13.15M | (4.95M) |
| Income Before Tax | (76.73M) | (62.19M) | (59.36M) | (44.6M) | (41.61M) |
| Pre-Tax Margin | -374.1% | -224.9% | -291.7% | -164.9% | -186.1% |
| Income Tax Expense | 32K | 4K | 64K | (1.85M) | 105K |
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Net Margin | -374.2% | -224.9% | -292.0% | -158.1% | -186.6% |
| EPS (Basic) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| EPS (Diluted) | (4.63) | (2.63) | (1.93) | (0.74) | 1.24 |
| Weighted Avg Shares | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
| Weighted Avg Shares (Diluted) | 16.59M | 23.64M | 28.37M | 40.42M | 49.63M |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.